Dendritic cell-based vaccines and therapies for cancer.
Dendritic cells (DCs) are the most potent professional antigen-presenting cells (APCs), and are capable of stimulating naive T cells and driving primary immune responses. Due to this unique property, DCs represent both vectors and targets for immunological intervention in numerous diseases and are optimal candidates for vaccination protocols in cancer. This review provides an overview of DC immunobiology and the integration of these important APCs in immunotherapies for cancer.
Tatsumi
Tomohide
T
L1.32e Hillman Cancer Centre-UPCI Research Pavillion, L5117 Center Avenue, Pittsburgh, PA 15213, USA.
Storkus
Walter J
WJ
D000818:Animals; D015551:Autoimmunity / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology* / Q000502:physiology; D006801:Humans; D007115:Immunization Schedule; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
D019496:Cancer Vaccines